Boehringer Ingelheim GMBH is becoming more active in the competitive oncology business development marketplace as the firm tries to broaden its footprint in cancer.
The closely guarded private firm has made oncology one of its core pillars as it has sharpened its research and...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

